Results 211 to 220 of about 6,354,899 (321)

Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND. [PDF]

Diabetes Care
Sattar N, Gerstein HC, D'Alessio D, Bhatt DL, Buse JB, Del Prato S, Kahn SE, Lincoff AM, McGuire DK, Nauck MA, Nissen SE, Zinman B, Zoungas S, Bartee A, Miller D, Nishiyama H, Qu Y, Weerakkody G, Wiese RJ, Pavo I, Nicholls SJ.   +20 more
europepmc   +1 more source

Driving continuous improvement of sustainability certification for industrial biobased systems through comprehensive sustainability requirements

Biofuels, Bioproducts and Biorefining, EarlyView.
Abstract Existing monitoring frameworks for sustainability certification schemes and labels (CSLs) have largely prioritised environmental aspects, while the social and economic pillars of sustainability remain comparatively underdeveloped. Also, dedicated circularity requirements tailored to biobased systems are still largely lacking, despite being ...
Iris Vural Gursel, Heleen Ballemans, Heike Axmann, Lesly Garcia‐Chavez, Marta Rodriguez‐Illera, Laura Väyrynen   +5 more
wiley   +1 more source

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database. [PDF]

Blood Cancer J
Bewersdorf JP, Kewan T, Lanino L, Wei W, Rudra Gupta T, Stempel JM, Al Ali NH, DeZern AE, Sekeres MA, Uy GL, Urrutia S, Carraway HE, Desai P, Griffiths EA, Stein EM, Brunner AM, McMahon C, Shallis RM, Zeidner JF, Savona MR, Hawkins H, Chandhok NS, Logothetis CN, Bidikian A, Getz TM, Roboz GJ, Rolles B, Wang ES, Harris AC, Amaya ML, Ball S, Grenet J, Xie Z, Madanat YF, Abaza Y, Badar T, Campos J, Haferlach T, Maciejewski JP, Sallman D, Enjeti A, Al-Rabi K, Halahleh K, Hiwase D, Diez-Campelo M, Valcarcel D, Haferlach C, Pleyer L, Kotsianidis I, Pappa V, Santini V, Consagra A, Al-Kali A, Ogawa S, Nannya Y, Stahl M, Della Porta MG, Komrokji RS, Zeidan AM.   +58 more
europepmc   +1 more source

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

British Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova, Yoana Lilova, Alexander Oscar, Alina Levi, Maria Kamusheva, Guenka Petrova   +5 more
wiley   +1 more source

Editors and Scientific Advisory Committee

, 2005
openaire   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

Sex Disparities in ACC Late-Breaking Cardiovascular Trials. [PDF]

JACC Adv
Moseley I, Correa A, Lin F, Lala-Trindade A, Bhatt DL, Shaw LJ.   +5 more
europepmc   +1 more source

Precision medicine in paediatrics: Progress and priorities

British Journal of Clinical Pharmacology, EarlyView.
Precision medicine is revolutionizing personalized healthcare, advancing both diagnostics and therapeutics at an unprecedented pace. Reviewing the paediatric applications of pharmacometrics, pharmacogenomics and advanced therapy medicinal products highlights not only the relevance of these exciting innovations to frontline care but also the significant
Nicola Husain, Claire Booth, Joseph F. Standing, Charlotte I. S. Barker   +3 more
wiley   +1 more source

Molecular Response, Event-Free Survival, and Treatment-Free Remission in Myeloproliferative Neoplasms: Update and Review with Insights from MPN Asia 2026. [PDF]

Curr Hematol Malig Rep
Abu-Zeinah G, Hobbs GS, Rampal RK, Lee SE, Gill H, Komrokji R, Tashi T, Bose P, Mascarenhas J, Yacoub A, Oh ST, Shimoda K, Reeves BN, Duan M, Yu LH, Qin A, Prchal JT, Kaushansky K, Mesa RA.   +18 more
europepmc   +1 more source

Decoding RNA regulation: Challenges and opportunities for RNA‐based therapies in Europe

British Journal of Clinical Pharmacology, EarlyView.
Abstract RNA‐based medicinal products represent a promising frontier in personalised medicine, offering sequence‐specific disease targeting at various molecular levels, yet their clinical translation in the European Union (EU) may be hindered by regulatory uncertainty around definitions and evidence requirements; this study therefore aims to identify ...
Olivia C. Lewis, Christine Leopold, Joyce M. Hoek, Raymond M. Schiffelers, Marie L. De Bruin   +4 more
wiley   +1 more source